Inactivation of uPA and its receptor uPAR by 3,3′-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration

Journal of Cellular Biochemistry

Volumn 107, Issue 3, 2009, Pages 516-527

  Ahmad, Aamir ^a   Kong, Dejuan ^a   Sarkar, Sanila H ^a   Wang, Zhiwei ^a   Banerjee, Sanjeev ^a   Sarkar, Fazlul H ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

3,3 diindolylmethane; Migration; MMP 9; PC3; Prostate cancer; uPA; VEGF

Indexed keywords

3,3' DIINDOLYLMETHANE; GELATINASE B; SMALL INTERFERING RNA; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENICITY; CELL MIGRATION; CELL STRAIN C4 2B; CELL STRAIN LNCAP; CELL STRAIN PC3; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; GENE SILENCING; HUMANS; INDOLES; MALE; MATRIX METALLOPROTEINASE 9; PROSTATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TRANSFECTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66749120029     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22152     Document Type: Article

References (36)

1. Ahmad A, Banerjee S, Wang Z, Kong D, Sarkar FH. 2008. Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-kappaB and Bcl-2. J Cell Biochem 105:1461-1471.
2. Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, Mager DE. 2004. Physiological modeling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos 32:632-638.
3. Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S, Sarkar FH. 2006. Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 66:10064-10072. (Pubitemid 44672060)
4. Binder BR, Mihaly J, Prager GW. 2007. uPAR-uPA-PAI-1 interactions and signaling: A vascular biologist's view. Thromb Haemost 97:336-342. (Pubitemid 46437793)
5. Blasi F, Carmeliet P. 2002. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932-943. (Pubitemid 35477371)
6. Carmeliet P, Moons L, Dewerchin M, Rosenberg S, Herbert JM, Lupu F, Collen D. 1998. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol 140:233-245. (Pubitemid 28070910)
7. Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH. 2001. Indole-3- carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 20:2927-2936. (Pubitemid 33027760)
8. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. 2008. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34:122-136.
9. Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, Cher ML. 2008. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia 10:439-449.
10. Ge Y, Elghetany MT. 2003. Urokinase plasminogen activator receptor (CD87): Something old, something new. Lab Hematol 9:67-71. (Pubitemid 37455806)
11. Heber D, Bowerman S. 2001. Applying science to changing dietary patterns. J Nutr 131:3078S-3081S. (Pubitemid 33070783)
12. Hong C, Kim HA, Firestone GL, Bjeldanes LF. 2002. 3,3′- Diindolylmethane (DIM) induces a G(1 cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 23:1297-1305. (Pubitemid 34905838)
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
14. Jo M, Thomas KS, Wu L, Gonias SL. 2003. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem 278:46692-46698. (Pubitemid 37452247)
15. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. 2007. Inhibition of angiogenesis and invasion by 3,3(-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67:3310-3319.
16. Koopman JL, Slomp J, de Bart AC, Quax PH, Verheijen JH. 1998. Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor. J Biol Chem 273:33267-33272. (Pubitemid 29005701)
17. Li Y, Cozzi PJ. 2007. Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev 33:521-527. (Pubitemid 47355340)
18. Li Y, Sarkar FH. 2002. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett 186:157-164. (Pubitemid 35246201)
19. Li Y, Li X, Sarkar FH. 2003. Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr 133:1011-1019. (Pubitemid 36407118)
20. Li Y, Chinni SR, Sarkar FH. 2005. Selective growth regulatory and proapoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 10:236-243. (Pubitemid 40543031)
21. Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, Reddy GP, Sarkar FH. 2007. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3′- diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 282:21542-21550. (Pubitemid 47099972)
22. Margheri F, D'Alessio S, Serrati S, Pucci M, Annunziato F, Cosmi L, Liotta F, Angeli R, Angelucci A, Gravina GL, Rucci N, Bologna M, Teti A, Monia B, Fibbi G, Del RM. 2005. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 12:702-714.
23. Nachshon-Kedmi M, Fares FA, Yannai S. 2004a. Therapeutic activity of 3,3′-diindolylmethane on prostate cancer in an in vivo model. Prostate 61:153-160. (Pubitemid 39244702)
24. Nachshon-Kedmi M, Yannai S, Fares FA. 2004b. Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3′-diindolylmethane through the mitochondrial pathway. Br J Cancer 91:1358-1363. (Pubitemid 39424798)
25. Nagai N, Okada K, Kawao N, Ishida C, Ueshima S, Collen D, Matsuo O. 2008. Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke. Neurosci Lett 432:46-49.
26. Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo R, Morton G, Danjoux C. 1999. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: An epidemiological analysis. J Urol 161:1521-1524. (Pubitemid 29420810)
27. Pillay V, Dass CR, Choong PF. 2007. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 25:33-39. (Pubitemid 46001467)
28. Pulukuri SM, Rao JS. 2007. Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res 67:6637-6646.
29. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS. 2005. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280:36529-36540. (Pubitemid 41633927)
30. Rao JS. 2003. Molecular mechanisms of glioma invasiveness: The role of proteases. Nat Rev Cancer 3:489-501. (Pubitemid 37328837)
31. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. 2000. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505-2514. (Pubitemid 30432515)
32. Savino JA III, Evans JF, Rabinowitz D, Auborn KJ, Carter TH. 2006. Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. Mol Cancer Ther 5:556-563.
33. Sheng S. 2001. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20:287-296. (Pubitemid 34595272)
34. Steinmetz KA, Potter JD. 1991. Vegetables, fruit, and cancer. I. Epidemiology. Cancer Causes Control 2:325-357.
35. Ustach CV, Kim HR. 2005. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 25:6279-6288. (Pubitemid 40946575)
36. Wang Y. 2001. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 21:146-170. (Pubitemid 32185245)